Adjuvant Therapy News and Research

RSS

Adjuvant Therapy is treatment given after the primary treatment to increase the chances of a cure. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, or biological therapy.

Study highlights accuracy of DecisionDx-Melanoma prognostic test in patients with Stage II-IIIA melanoma

Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced the presentation of data highlighting how the accuracy of the DecisionDx-Melanoma gene expression profile (GEP) test in patients with Stage II and IIIA melanoma can improve adjuvant clinical trial design at the 2018 Society for Melanoma Research International Congress held in Manchester, England from October 24-27.

30 Oct 2018

Mayo Clinic physicians win SU2C Catalyst Award to fund melanoma research

Mayo Clinic physicians Matthew Block, M.D., Ph.D. and Tina Hieken, M.D., have received a Stand up to Cancer Catalyst Award to fund melanoma research and a neoadjuvant clinical trial.

7 Sep 2018

Novartis' new drug combination receives positive CHMP opinion for treating stage III BRAF mutant melanoma

Novartis today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of Tafinlar® in combination with Mekinist® for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.

27 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Adjuvant therapy may not improve survival for rare cancers

A recent study found that adjuvant therapy following surgical removal of a rare form of gastrointestinal tumor has no effect on survival rates for patients.

26 Mar 2018

Adjuvant therapy after surgical removal of rare tumors may not provide survival benefit

Results of an analysis from the University of Cincinnati College of Medicine show that additional therapy, or adjuvant therapy, delivered after surgical removal of a rare type of gastrointestinal tumor does not increase survival rates for patients.

26 Mar 2018

Researchers block common siren call of glioblastoma and metastatic breast cancer

Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

23 Jan 2018

Breast cancer adjuvant treatment discordance linked to general distrust in healthcare system

Nearly one-third of women with breast cancer went against their doctor's advice and chose not to begin or complete the recommended adjuvant anti-cancer therapy to kill residual tumor cells following surgery, according to a study led by a Johns Hopkins Bloomberg School of Public Health researcher.

1 Nov 2017

Combination therapy found to be effective adjuvant treatment option in melanoma patients

Combination targeted adjuvant therapy with dabrafenib and trametinib doubles relapse-free survival in patients with stage III BRAF-mutant melanoma, according to late-breaking results from the COMBI-AD trial presented today at the ESMO 2017 Congress in Madrid and published in the New England Journal of Medicine.

11 Sep 2017

Study describes link between key melanoma signaling pathway and novel class of drugs

Results of a study by The Wistar Institute have described a correlation between a key melanoma signaling pathway and a novel class of drugs being tested in the clinic as adjuvant therapy for advanced melanoma, providing useful information for a more effective use of this type of treatment.

7 Sep 2017

Increased genomic risk can make small tumors aggressive, study says

A study conducted on patients with early stage breast cancer suggested that even small tumors that are thought to be less serious can be aggressive.

4 Sep 2017

Immune booster could improve effectiveness of vaccines and cancer immunotherapy

Vaccines and cancer immunotherapies do essentially the same thing: They boost a person's immune system, better enabling it to fight an offender, be it microbe or malignancy.

29 Aug 2017

UAlberta researchers find strong clues to underlying cause of HIV-associated neurocognitive disorders

UAlberta researchers believe they now have a clearer picture of why people living with HIV so commonly suffer from dementia and other neurocognitive disorders.

20 Jul 2017

FDA approves first extended adjuvant therapy to lower risk of breast cancer recurrence

The U.S. Food and Drug Administration today approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer.

18 Jul 2017

Lymph node removal may not be needed for all melanoma patients, study finds

Many patients with melanoma need a sentinel-lymph-node biopsy to determine if cancer cells have spread there, but a positive finding doesn't mean all the lymph nodes in the area must be removed, according to new international study.

17 Jul 2017

Adherence to NCCN Guidelines spares breast cancer patients from unnecessary tests

According to SEER data, more than 260,000 women were diagnosed with breast cancer in the United States in 2016, most of whom were diagnosed with early-stage (stage I or II) disease.

21 Jun 2017

Adding a second HER2-targeted treatment may improve outcomes for some women with breast cancer

A phase III clinical trial of 4,805 women with HER2-positive breast cancer suggests adding a second HER2 targeted medicine, pertuzumab (Perjeta), to standard of care trastuzumab (Herceptin) after surgery may help, although the benefit is modest.

6 Jun 2017

Study shows effectiveness of 3 months of chemotherapy in colon cancer patients after surgery

After surgery for lymph-node positive colon cancer (stage III), some patients may only need half of the long-standing standard course of chemotherapy.

5 Jun 2017

Targeted therapy appears to be more effective in preventing lung cancer recurrence

The targeted therapy gefitinib appears more effective in preventing recurrence after lung cancer surgery than the standard of care, chemotherapy.

18 May 2017

ASTRO issues new clinical guideline for management of oropharyngeal cancer with radiation therapy

The American Society for Radiation Oncology today issued a new clinical guideline for the management of oropharyngeal cancer.

17 Apr 2017